FDA finding on Xiaflex expected in September

August 26th, 2013

xiaflex peyronies disease

Will the FDA approve the Auxilium drug Xiaflex for Peyronie’s Disease?  News is expected during the first week of September.  Xiaflex consists of an enzyme which breaks down the plaque that causes curvature of the penis.  Trial studies indicate that the drug can reduce the degree of penile curvature in Peyronie’s disease and other symptoms for men with the disease, and results have been consistent in multiple phases. Urosciences will watch the Web for the latest news on Xiaflex for Peyronie’s Disease, and keep our viewers posted.  The drug is already in use for a crippling hand condition known as Dupuytren’s contracture.

This post was written by  UroSciences, developers of the PDAD Peyronie’s Disease Assessment Device for urologists and patients.

Join Urosciences on FaceBook and Twitter.




False positives on thousands of prostate cancer tests

August 26th, 2013

prostate cancer news

ABC News  is reporting that thousands of men in Pennsylvania, and possibly the world over,  may have received erroneous PSA test results showing higher than actual levels–and possibly leading to unnecessary biopsies.  PSA, or prostate specific antigen levels, are a benchmark physicians use to gauge the likelihood of prostate cancer in their patients.  According to the report,  the makers of the test issued a global recall in June, citing a 20-23% “positive bias”.  The specific product recalled is the Immulite PSA test.

Read more posts on prostate cancer news:

Sex After Radical Prostatectomy

Preventing Climacturia (Urine leakage during sex)

Exosomes and Prostate Cancer Diagnosis





Peyronie’s disease: Our top blog posts

August 26th, 2013

peyronies disease man

If you want to learn more about the history and treatment of Peyronie’s disease, we’ve posted our top blog entries on the subject here for your convenience.  When you’ve finished reading, be sure to view the PDAD device, a tool for both urologists and patients for the diagnosis and assessment of PD.

Here are links to our top posts for Peyronie’s disease information:

10 Interesting Facts About Peyronie’s :  A quick compilation of things you might not know, like how Peyronie’s disease, or penile curvature, got its name, how many are affected by it, and which men should be most concerned.

Getting Treatment for Peyronie’s:  Overcoming embarrassment and getting treatment for curvature of the penis can be the most difficult step of all.  Here are some things you might not have thought about to get you started.

ED, Diabetes and Peyronie’s:  Why men with ED and diabetes should be aware of the possibility of Peyronie’s disease.

Collagenase Injections for Peyronie’s Disease:  Read more about this treatment.



Male pattern baldness drug finasteride for prevention of prostate cancer?

August 26th, 2013


In what looks to be an unlikely headline, some experts may be ready to endorse finasteride treatment as a preferred choice in the prevention of prostate cancer.  The drug, used to treat male pattern baldness and enlarged prostate, was black boxed by the FDA about ten years ago for use as a prostate cancer preventative, due to study results that showed a possible increase in more aggressive prostate tumors.

But, a new study indicates that among men aged 62, who received finasteride for a period of seven years, were 30% less likely to develop prostate cancer.  And, the risk of less aggressive prostate tumors was reduced by more than 40%.  Based on these results, it can be estimated that finasteride could prevent more than 70,000 cases of prostate cancer every year.  While the study also showed a 3% increased likelihood of more aggressive tumors, it is thought that this could be the result of finasteride reducing the size of the prostate, and thereby making the tumors easier for physicians to find.

Are you or a loved one recovering from prostate cancer or radical prostatectomy?  Read more about the UroStop device for preventing urine leakage during sex, or climacturia, after prostate surgery–developed by UroSciences.

The UroStop variable tension penile loop for sexual incontinence.

The UroStop variable tension penile loop for sexual incontinence.



CyberKnife Robotic Radio Surgery System and prostate cancer treatment

August 21st, 2013

prostate cancer cyberknife

Today we’ve gathered information from around the Web on CyberKnife treatments for prostate cancer.   If you aren’t familiar with CyberKnife, here is some general information:

CyberKnife is used for the highly-targeted delivery of radiation impulses directly to the site of tumors within the body.  The pulses, as many as 200 per treatment, are delivered from many angles through the use of a robotic arm similar to those associated with assembly lines in the automotive industry.  The treatments last for 1-2 hours per day for approximately five days.

In comparison to traditional radiation therapy for prostate cancer, or other cancers, which lasts approximately eight weeks,  CyberKnife treatment offers a much more convenient option, and reduces lodging costs for those who must travel long distances to obtain the therapy.  The side effects of CyberKnife therapy are reported by some to be much milder than traditional radiation treatments.  Some patients report fatigue, urgency in urination, and irritation of the urethra after CyberKnife treatments.

Check with your insurance company if you are considering CyberKnife treatments to assure coverage.  In addition, Medicare patients should inquire about coverage, as CyberKnife therapy is not covered in some regions–and restrictions may apply even in regions where it is covered.

If you or a loved one is battling prostate cancer, be sure to check out our other Urosciences posts on sex after radical prostatectomy and urine leakage during sex, also known as climacturia.



Prostate Cancer News: Are exosomes the future of prostate cancer diagnosis?

August 13th, 2013

prostate cancer test

A new in vitro diagnostic test for prostate cancer may be on the way to replacing the traditional PSA test and perhaps some biopsy procedures.  The test is known as EXO106, which focuses on identifying the novel 4 gene prostate cancer signature.  Exosomes are substances within human cells carrying nucleic acids which are unique to specific diseases. By testing blood or urine,  it can be determined if an exosome related to a specific disease is present.  In addition, EXO106 may also be able to predict the severity of prostate cancer and how well the prostate cancer is responding to treatment.

Thank you for visiting UroSciences, makers of the UroStop device for preventing climacturia or urine leakage during sex after  radical prostatectomy (prostate surgery).

Article source: http://medcitynews.com/2013/08/new-non-invasive-test-for-prostrate-cancer-may-identify-severity-of-tumor-also/

10 Interesting facts about Peyronie’s disease

August 13th, 2013

peyronies disease

At UroSciences, we’re always combing the Web for the latest information on Peyronie’s Disease, prostate cancer, and other urology news.  Below, we’ve compiled some interesting facts on Peyronie’s Disease that you may not have realized before:

  • Peyronie’s disease, also known as curvature of the penis, has been referenced in history since the 1300’s.
  • The disease was named for the personal physician of Louis XV, King of France.
  • Peyronie’s disease affects an estimated 3-9 percent of men.
  • PD is most commonly seen in Caucasian males over the age of 40.
  • Blood type A+ is most commonly associated with Peyronie’s
  • Peyronie’s disease is a listed side effect of some beta blocker medications.
  • Approximately 3 in 10 men with Peyronie’s disease also have other connective tissue disorders of the hands, and sometimes, feet.
  • Men as young as 18 are affected by Peyronie’s
  • CITA is an acronym for chronic inflammation of the tunica albuginea.
  • Depression and withdrawal is common among men with Peyronie’s Disease.

For more information, we invite you to view some of our other blog posts, including overcoming embarrassment and getting help for Peyronie’s disease, and the PDAD (Peyronie’s Disease Assessment Device) for patients and urologists



Men with ED, diabetes, often unaware of Peyronie’s Disease

August 7th, 2013

The P.D.A.D., Peyronie’s Disease Assesment Device, by UroSciences

If you have erectile dysfunction, you may want to consult with your urologist on the possible presence of Peyronie’s Disease–especially if you also have diabetes. Recent studies suggest that men with erectile dysfunction may not be aware that they also have Peyronie’s Disease, and that it could be contributing to their ED symptoms. And, in men with both ED and Peyronie’s disease, who were previously unaware of their Peyronie’s, diabetes was also present in 40% of cases.  The study, conducted in Istanbul, Turkey, suggests that Peyronie’s disease should always be suspected in men with both ED and diabetes.

More UroSciences posts on Peyronie’s Disease news:

Overcome Embarrassment and Get Treatment for Peyronie’s Disease

The PDAD Device for Peyronie’s

Collagenase Injections for Peyronie’s Disease

3 Resources for Peyronie’s Disease




Xofigo prostate cancer drug reported to reduce pain

August 7th, 2013


Xofigo, a newly approved treatment for advanced prostate cancer that has spread to the bones, is said to reduce patient pain levels.  The drug, which mimics calcium by binding to bone tissue at tumor sites, has been shown to extend patient survival rates by three months. The binding action of  Xofigo allows physicians to target the precise location of bone tumors caused by prostate cancer, and minimizes bone damage caused by tumors.  It is reported that Xofigo may allow patients to delay chemotherapy and the use of morphine for pain management.  A Xofigo treatment can be administered in a few as 15 minutes.

This prostate cancer news is brought to you by UroSciences– makers of the UroStop variable tension penile loop for sexual incontinence and the PDAD Peyronie’s disease assessment device.



New Mexico Cancer Center offering Xofigo for prostate cancer

August 7th, 2013


The New Mexico Cancer Center has begun offering Xofigo to its prostate cancer patients.   Made by Bayer Healthcare, Xofigo, radium -223, has shown promise in recent studies for extending the survival rates of patients with advanced prostate cancer.  Xofigo works by mimicking calcium within the body and binding to areas of rapid bone growth caused by bone tumors, thus limiting the damage caused by the tumors.  Xofigo, once known as Alpharadin, received marketing approval from the FDA on May 15, 2013.


Check in with our UroSciences blog for the very latest news on prostate cancer, Peyronie’s disease, climacturia, and other urology topics.  Learn more about our PDAD device for assessing Peyronie’s disease, and the UroStop for preventing urine leakage during sex.

The UroStop variable tension penile loop for sexual incontinence.

The UroStop variable tension penile loop for sexual incontinence.